Emcure Pharmaceuticals Limited
EMCURE · Pharma · NSE
₹1,731
Current Market Price
Fair Value (DCF)
₹882
Discount to FV
-49.1%
Updated just now
YieldIQ Score
38/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
55%
ROE
18.7%
Debt/Equity
0.31
WACC
12.8%
Market Cap
₹32,834 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
28.5%
Return on capital employed
EV / EBITDA
19.5×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
7.9×
EBIT covers interest
Current Ratio
1.71×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.0%
3-year revenue growth
Revenue CAGR (5Y)
8.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,731.2
Bear case
Discount -222.5%
Base case
Discount -96.4%
Bull case
Discount -56.8%
Ratio Trends
EMCURE · last 5 annual periods
ROE
18.7%
ROCE
28.5%
Operating Margin
—
Debt / Equity
0.31×
PE
—
EV / EBITDA
—
Historical Financials
EMCURE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹5766 Cr | ₹5931 Cr | ₹6582 Cr | ₹7896 Cr | ₹9204 Cr | +12.4% |
| EBITDA | ₹1350 Cr | ₹1170 Cr | ₹1240 Cr | ₹1531 Cr | ₹1846 Cr | +8.1% |
| EBIT | ₹1105 Cr | ₹910 Cr | ₹928 Cr | ₹1111 Cr | — | +0.1% |
| PAT | ₹662 Cr | ₹532 Cr | ₹498 Cr | ₹681 Cr | ₹924 Cr | +8.7% |
| EPS (diluted) | ₹36.63 | ₹29.43 | ₹27.57 | ₹36.43 | — | -0.1% |
| CFO | ₹768 Cr | ₹747 Cr | ₹1097 Cr | ₹852 Cr | ₹944 Cr | +5.3% |
| CapEx | ₹-397 Cr | ₹-403 Cr | ₹-307 Cr | ₹-407 Cr | ₹-548 Cr | — |
| FCF | ₹371 Cr | ₹343 Cr | ₹790 Cr | ₹445 Cr | ₹396 Cr | +1.6% |
| Total Assets | ₹6063 Cr | ₹6673 Cr | ₹7806 Cr | ₹8233 Cr | ₹9612 Cr | +12.2% |
| Total Debt | ₹2217 Cr | ₹2334 Cr | ₹2335 Cr | ₹1023 Cr | ₹1521 Cr | -9.0% |
| Shareholders' Equity | ₹1988 Cr | ₹2501 Cr | ₹2952 Cr | ₹4446 Cr | ₹4950 Cr | +25.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
EMCURE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 JBCHEPHARM JBCHEPHARM | — | — | Pending | 17.1% | 46.7× |
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 AJANTPHARM AJANTPHARM | — | — | Pending | 23.3% | 33.2× |
 IPCALAB IPCALAB | — | — | Pending | 14.2% | 35.6× |
 WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹3.00/sh
Last payout
2025-08-14
₹3.00
Peak payout
₹3.00
Trailing yield
0.17%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Emcure Pharmaceuticals Limited (EMCURE.NS) trades at 1731.20 vs a model fair value of 881.58, a gap of -49.1%. Piotroski F-score: 4/9. Mo...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of EMCURE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for EMCURE →
Compare
Head-to-head with peers
Compare EMCURE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse EMCURENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.